Asan Medical center

Phase	Trial	Trial Status [asc]	Site Status	Drug	NCT#
2	5 Years of Adjuvant Imatinib in Patients With Gastrointestinal Stromal Tumor With a High Risk	Recruiting	Active	Imatinib	NCT05385549
2	Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)	Recruiting	Active	Belzutifan	NCT04924075
2	The Efficacy and Safety of Temozolomide in SDH-deficient GIST (GIST)	Recruiting	Active	Temozolomide	NCT05661643
2	Rivoceranib Plus Paclitaxel in Patients With Gastrointestinal Stromal Tumor	Recruiting	Active	Rivoceranib + Paclitaxel	NCT05905887
3	Study of IPI-504 in GIST patients following failure of at least imatinib and sunitinib	Terminated	Closed	IPI-504	NCT00688766
2	A Study of Intermittent Dosing Schedule of Imatinib in Patients With Tyrosine Kinase Inhibitor Refractory GISTs	Unknown	Active	Imatinib	NCT02712112
1	Dovitinib in Combination With Imatinib in Patients With Gastrointestinal Stromal Tumors	Withdrawn	Not yet activated	Imatinib + Dovitinib	NCT02268435